Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives

Min Zhong, Ying Lü, Shaolei Li, Xiaolong Li, Zhenming Liu, Xianran He, Yongmin ZhangEuropean 2023 · DOI

TL;DR

Researchers have developed a new class of hybrid molecules by fusing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Ebselen, a potent organoselenium compound. These "NSAIDs-EBS" derivatives, particularly the aspirin-based compound 5j, demonstrate remarkable anticancer activity and antioxidant properties by targeting the enzyme Thioredoxin Reductase 1 (TrxR1), outperforming both their parent compounds and some standard clinical benchmarks in lab tests.

What Problem Does This Paper Address?

While NSAIDs like aspirin and ibuprofen are household names for pain and inflammation, they have also shown promise in cancer prevention and treatment. However, their standalone anticancer potency is relatively weak. On the other hand, selenium-containing compounds like Ebselen are known for their ability to manage oxidative stress and kill tumor cells, but they often lack specificity.

The authors address the need for more effective, multi-targeted anticancer agents. By using a "hybridization strategy," they aimed to combine the structural frameworks of NSAIDs with the redox-active Ebselen moiety to create synergistic molecules that can better disrupt the internal balance (homeostasis) of cancer cells.

Methods

The research team synthesized two distinct series of hybrid molecules:

  • Series 5a-j: Utilized a phenyl (benzene ring) linker between the NSAID and Ebselen.
  • Series 9a-i: Utilized an ethyl (two-carbon chain) linker.

The study employed a multi-disciplinary evaluation approach:

  1. Cytotoxicity Testing: MTT assays were used to measure how effectively the compounds killed five different human cancer cell lines (gastric, colon, breast, cervical, and lung).
  2. Antioxidant Assays: The team tested the compounds' ability to scavenge radicals (DPPH assay), prevent DNA damage (bleomycin assay), and mimic the natural enzyme Glutathione Peroxidase (GPx).
  3. Mechanism Study: They performed enzymatic inhibition assays against TrxR1 (an enzyme often overexpressed in cancer) and used molecular docking (computer simulations) to visualize how the molecules bind to the enzyme's active site.

Datasets

As this is a medicinal chemistry paper, "datasets" refers to the biological models and benchmarks used for evaluation:

  • Cell Lines: BGC-823 (gastric), SW480 (colon), MCF-7 (breast), HeLa (cervical), and A549 (lung).
  • Reference Compounds: Aspirin, Ibuprofen, Naproxen, and Ebselen (parent compounds); Doxorubicin (standard chemotherapy benchmark); and Auranofin (standard TrxR1 inhibitor benchmark).
  • Protein Structure: The crystal structure of mammalian TrxR1 (PDB ID: 1H6V) was used for molecular modeling.

Key Insights and Ideas

  • Synergy through Hybridization: The hybrid molecules were significantly more potent than their parent NSAIDs or Ebselen alone. While the parent drugs were often inactive at doses up to 50 μM, the hybrids worked at low micromolar levels.
  • Linker Chemistry Matters: Series 5 (phenyl linker) generally outperformed Series 9 (ethyl linker). The authors attribute this to the increased lipophilicity and electron-withdrawing effects of the benzene ring, which likely helps the drug penetrate cell membranes and bind more effectively to targets.
  • TrxR1 as a Vulnerability: The study confirms that targeting the Thioredoxin system is a viable strategy. Cancer cells rely heavily on TrxR1 to manage the high levels of reactive oxygen species (ROS) they produce; by inhibiting this enzyme, the hybrids "turn off" the cell's antioxidant defense, leading to cell death.

Key Results

  • Potent Cytotoxicity: Compound 5j (the aspirin-Ebselen hybrid) was the standout, with $IC_{50}$ values below 3 μM across all tested cancer lines. It was particularly effective against breast cancer (MCF-7, 1.5 μM) and cervical cancer (HeLa, 1.7 μM).
  • Superior Enzyme Inhibition: Compound 5j inhibited TrxR1 with an $EC_{50}$ of 8.8 nM, making it significantly more potent than the clinical benchmark Auranofin (22.4 nM).
  • Enhanced Antioxidant Activity: In GPx-like assays, compound 5j was roughly three times more active than Ebselen itself.
  • Docking Validation: Computer modeling showed that the selenium atom in the hybrids sits in close proximity to the cysteine residues (Cys497/Cys498) in the TrxR1 active site, providing a structural explanation for its high inhibitory activity.

Limitations and Future Work

  • In Vitro Focus: The study was conducted entirely in cell cultures and test tubes. The authors acknowledge that the next step must involve in vivo (animal) studies to see how these compounds behave in a complex biological system.
  • Selectivity: While the compounds kill cancer cells effectively, the paper does not extensively discuss their effect on healthy, non-cancerous cells. Establishing a "therapeutic window" is essential for drug development.
  • Optimization: Future work will likely focus on further refining the chemical scaffold to improve drug-like properties, such as solubility and metabolic stability.

Summary updated

BibTeX
@inproceedings{zhong2023synthesis,
  author = {Min Zhong and Ying Lü and Shaolei Li and Xiaolong Li and Zhenming Liu and Xianran He and Yongmin Zhang},
  title = {{Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives}},
  booktitle = {European},
  year = {2023},
  doi = {10.1016/j.ejmech.2023.115662},
}
Figure